Breaking News
Quotes
All Instrument Types
  • All Instrument Types
  • Indices
  • Equities
  • ETFs
  • Funds
  • Commodities
  • Currencies
  • Crypto
  • Bonds
  • Certificates

Please try another search

Search website for: 
Popular News
More
Popular Analysis
More
More
Get 40% Off
/Free Sign Up
 0
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list
Close

Algernon Pharmaceuticals Inc Class A (AGN)

Create Alert
Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Create Manage my alerts 
Back
Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
 
Create New Watchlist Create
Create a new holdings portfolio Add Create
+ Add another position Close
0.090 -0.010    -10.00%
19/04 - Closed. Currency in CAD ( Disclaimer )
  • Volume: 45,888
  • Bid/Ask: 0.090 / 0.115
  • Day's Range: 0.090 - 0.090
Type:  Equity
Market:  Canada
Algernon Pharma 0.090 -0.010 -10.00%

AGN Financial Summary

 
A brief financial summary of Algernon Pharmaceuticals Inc Class A as well as the most significant critical numbers from each of its financial reports. In addition, some financial ratios derived from these reports are featured. Users can opt to see 4 periods of either annual or quarterly information.

Algernon Pharmaceuticals Inc. reported earnings results for the third quarter and nine months ended May 31, 2023. For the third quarter, the company reported net loss was CAD 1.13 million compared to CAD 0.800161 million a year ago. Basic loss per share from continuing operations was CAD 0.1 compared to CAD 0.12 a year ago.For the nine months, net loss was CAD 4.25 million compared to CAD 3.84 million a year ago. Basic loss per share from continuing operations was CAD 0.42.

AnnualQuarterly  
InvestingPro Advanced Financial Summary
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

AGN Income Statement

Gross margin TTM -
Operating margin TTM 0%
Net Profit margin TTM 0%
Return on Investment TTM -115.97%
 Total Revenue  Net Income
Period Ending: Nov 30, 2023 Aug 31, 2023 May 31, 2023 Feb 28, 2023
Total Revenue
Gross Profit
Operating Income -0.503 -0.951 -1.06 -1.2
Net Income -0.522 -2.53 -1.13 -1.25

AGN Balance Sheet

Quick Ratio MRQ 0.03
Current Ratio MRQ 0.04
LT Debt to Equity MRQ -
Total Debt to Equity MRQ -
 Total Assets  Total Liabilities
Period Ending: Nov 30, 2023 Aug 31, 2023 May 31, 2023 Feb 28, 2023
Total Assets 3.95 4.19 6.14 6.03
Total Liabilities 2.94 2.72 2.41 2.45
Total Equity 1.01 1.47 3.72 3.59

AGN Cash Flow Statement

Cash Flow/Share TTM -0.11
Revenue/Share TTM -
Operating Cash Flow  -1.77%
 Cash  Net Change in Cash
Period Ending: Nov 30, 2023 Aug 31, 2023 May 31, 2023 Feb 28, 2023
Period Length: 0 Months 0 Months 0 Months 0 Months
Cash From Operating Activities -0.052 -0.573 -0.733 -0.44
Cash From Investing Activities -0.006 -0.027 -0.009
Cash From Financing Activities 0.269 0.974 -0.017
Net Change in Cash -0.051 -0.309 0.214 -0.469
* In Millions of CAD (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

I Agree

AGN Comments

Write your thoughts about Algernon Pharmaceuticals Inc Class A
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Pouria Mehrabi
Pouria Mehrabi Dec 14, 2020 12:57
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Big news comin soon! Buckle up
Reply
3 1
Report
Mike Wolbeck
Mike Wolbeck Dec 03, 2020 12:13
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
why we going down again?
Reply
0 0
Report
Gary Coulter
QuantaBe Sep 22, 2020 15:18
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
If you have already invested, then stay put.  Otherwise, it's a wait and see over the next 3 -6 months until positive results start moving towards some proven results which will ultimately lead to sales traction in various markets around the world.  No, a vaccine created in the UK, US or otherwise will not be the killer of ifenprodil treatments worldwide.  Expect to see above .50 and beyond for end of March of 2021.
Reply
0 0
Report
Mike Ivanitz
Mike Ivanitz Sep 10, 2020 20:05
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
How about now?
Reply
0 0
Report
Shawn Francis
Shawn Francis Aug 19, 2020 11:03
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Anybody on the fence better load up now...
Reply
0 0
Report
Shawn Francis
Shawn Francis Aug 19, 2020 11:02
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Anybody on the fence better load up now...
Reply
0 0
Report
Attilio Cascegna
Attilio Cascegna Aug 05, 2020 9:41
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
09:30 Wed 05 Aug 2020Algernon says first patient dosed in Phase 2 study of Ifenprodil as a treatment in idiopathic pulmonary fibrosis and chronic cough
Reply
2 2
Report
Pouria Mehrabi
Pouria Mehrabi Jul 17, 2020 13:01
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Gonna pass 50 cents with new positive results soon
Reply
2 0
Report
Lagman Johann
Lagman Johann Jun 18, 2020 3:34
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
This companies full of shit
Reply
0 4
Report
Gary Coulter
QuantaBe Jun 04, 2020 14:26
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Algernon is starting to appear as a hidden gem among traditional BioTech 'buy and hope' purchases by the public.  Ifenprodil has been proven in the past, and is gaining more attention as a leading runner for 'treatment' of Covid-19 versus wishful thinking for a near term Vaccine/Cure.  Positive support for investigative trials in South Korea, Australia, Canada, and now the US is warming up as well.  Management has a strong position of awareness of the future outlook and complexities of the upcoming trials.  Minimum 6 month position recommended, with 12-18 months more realistic of expectations of turning a healthy return on your investment.  If you have the patience for the medium term, this could provide you with exceptional returns.
Reply
1 0
Report
Lagman Johann
Lagman Johann Jun 04, 2020 14:26
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
How can they say they are cautioning that Ifenprodil is not expresing to treat covid 19 when they testing it to treat it....
Reply
0 0
Report
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Cancel Attach
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Confirm Block Cancel
Ok
Report this comment

I feel that this comment is:

Submit
Comment flagged

Thank You!

Your report has been sent to our moderators for review
Close
Continue with Google
or
Sign up with Email